Get the Stockscreener App
28.50
2.30%
-0.67
Alkermes Plc stock is traded at $28.50, with a volume of 1.48M.
It is down -2.30% in the last 24 hours and down -9.25% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$29.17
Open:
$29.26
24h Volume:
1.48M
Relative Volume:
0.64
Market Cap:
$4.71B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
14.62
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
-3.46%
1M Performance:
-9.25%
6M Performance:
-7.41%
1Y Performance:
-6.56%
1-Day Range:
$28.42
$29.35
1-Week Range:
$27.80
$29.80
52-Week Range:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
28.50 | 4.82B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-25 | Initiated | Truist | Buy |
| Sep-26-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jun-17-25 | Upgrade | UBS | Neutral → Buy |
| May-28-25 | Initiated | Needham | Buy |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Frazier Life Sciences Management L.P. Boosts Stock Position in Alkermes plc $ALKS - MarketBeat
EcoR1 Capital LLC Makes New Investment in Alkermes plc $ALKS - MarketBeat
Retail Surge: Why global investors buy Alkermes plc 8AK stockCEO Change & Expert Curated Trade Ideas - moha.gov.vn
History Review: Will Alkermes plc 8AK stock test record highs in 2025Watch List & High Conviction Investment Ideas - moha.gov.vn
BlackRock increases stake in Alkermes to 17% By Investing.com - Investing.com South Africa
BlackRock increases stake in Alkermes to 17% - Investing.com
Stempoint Capital LP Acquires 158,772 Shares of Alkermes plc $ALKS - MarketBeat
First Trust Advisors LP Has $39.98 Million Stock Holdings in Alkermes plc $ALKS - MarketBeat
Alkermes, Avadel Pharmaceuticals merger gets HSR clearance in US - MLex
Avadel Pharmaceuticals Acquisition by Alkermes Advances - TradingView — Track All Markets
Are Investors Undervaluing Alkermes (ALKS) Right Now? - sharewise.com
(ALKS) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Schroder Investment Management Group Invests $1.39 Million in Alkermes plc $ALKS - MarketBeat
Insider Selling: Alkermes (NASDAQ:ALKS) EVP Sells 3,748 Shares of Stock - MarketBeat
Alkermes raises Avadel buyout offer after Lundbeck’s unsolicited bid - MSN
Norges Bank Invests $53.33 Million in Alkermes plc $ALKS - MarketBeat
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - MSN
Avadel Pharmaceuticals plc and Alkermes plc Announce Proposed Transaction for Acquisition - Quiver Quantitative
Announcement relating to despatch of Rule 15 proposal - The Manila Times
Avadel (NASDAQ: AVDL) sends Rule 15 proposal to equity holders in Alkermes deal - Stock Titan
Capital Fund Management S.A. Makes New $1.14 Million Investment in Alkermes plc $ALKS - MarketBeat
Will Alkermes plc (8AK) stock sustain bullish trend into 2025Fed Meeting & Smart Money Movement Tracker - Newser
ALKS: Elixirxton demonstrates strong efficacy, safety, and dosing flexibility for narcolepsy and hypersomnolence - TradingView
Avadel Pharmaceuticals Announces Mailing of Definitive Proxy Statement Regarding Proposed Acquisition by Alkermes - Quiver Quantitative
Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting - Benzinga
Avadel (Nasdaq: AVDL) mails proxy, sets Jan. 12 scheme and EGM on Alkermes deal - Stock Titan
VP Hopkinson Files To Sell 3,748 Of Alkermes PLC [ALKS] - TradingView
Mackenzie Financial Corp Acquires 53,323 Shares of Alkermes plc $ALKS - MarketBeat
Evercore Healthcare Conference - marketscreener.com
How Alkermes plc (8AK) stock valuation compares with sectorQuarterly Profit Report & Daily Profit Focused Screening - Newser
Is Alkermes plc (8AK) stock a safe buy pre earningsMarket Growth Summary & Real-Time Sentiment Analysis - Newser
Insider Selling: Alkermes (NASDAQ:ALKS) EVP Sells 4,000 Shares of Stock - MarketBeat
Regeneron, Tessera to advance gene editing therapy for AATD: Deals Report - BioCentury
How supply chain issues affect Alkermes plc stockPortfolio Performance Report & Real-Time Stock Movement Alerts - Newser
Should Alkermes (ALKS) Investors Reassess Prospects After Raised 2025 Guidance and Strong Q3 Results? - Yahoo Finance
Is Alkermes plc (8AK) stock among top earnings playsQuarterly Trade Review & Real-Time Volume Surge Alerts - Newser
Insider Sell: Craig Hopkinson Sells 4,000 Shares of Alkermes PLC (ALKS) - GuruFocus
Alkermes plc. Officer Sells 4,000 Shares - TradingView
VP Hopkinson Sells 4,000 ($117.2K) Of Alkermes PLC [ALKS] - TradingView
Avadel Pharmaceuticals plc Announces Scheme Meeting for Alkermes Acquisition Proposal - Quiver Quantitative
Avadel Pharmaceuticals (Nasdaq: AVDL) to hold Scheme and EGM on Alkermes takeover Jan. 12 - Stock Titan
Rhumbline Advisers Purchases 17,660 Shares of Alkermes plc $ALKS - MarketBeat
Legal & General Group Plc Sells 17,227 Shares of Alkermes plc $ALKS - MarketBeat
Loomis Sayles & Co. L P Sells 330,389 Shares of Alkermes plc $ALKS - MarketBeat
JPMorgan Chase & Co. Trims Stock Position in Alkermes plc $ALKS - MarketBeat
Alkermes plc $ALKS Shares Sold by Ensign Peak Advisors Inc - MarketBeat
JPMorgan discloses securities dealings in Avadel Pharmaceuticals - Investing.com
Alkermes Eyes Global Phase 3 Trial After Encouraging Data From Sleep Disorder Study - Sahm
Why Is Alkermes (ALKS) Down 5.5% Since Last Earnings Report? - sharewise.com
Avadel (AVDL) Drops 6.7% on Lack of Leads - Finviz
Lundbeck Concedes Avadel Bidding War, But Remains On The Hunt - Citeline News & Insights
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.48%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):